{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:49:52Z","timestamp":1791467392842,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"S14","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johannes Kepler University Linz"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Das Lungenkarzinom ist in \u00d6sterreich eine der h\u00e4ufigsten Krebstodesursachen und wird h\u00e4ufig erst in fortgeschrittenen Stadien diagnostiziert. Internationale Studien belegen, dass ein strukturiertes Screening mittels Niedrigdosiscomputertomographie die lungenkrebsbedingte Sterblichkeit senkt und die Diagnose in fr\u00fchere, kurativ behandelbare Stadien verlagert. Ziel dieses Positionspapiers ist es, eine evidenzbasierte Grundlage f\u00fcr die Einf\u00fchrung eines nationalen Lungenkarzinom-Screening-Programms in \u00d6sterreich zu schaffen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methoden<\/jats:title>\n                    <jats:p>Grundlage des Positionspapiers waren die verf\u00fcgbare internationale Evidenz, aktuelle europ\u00e4ische Leitlinien und Empfehlungen sowie \u00f6sterreichische epidemiologische und gesundheits\u00f6konomische Daten. Vertreter:innen der \u00d6sterreichischen R\u00f6ntgengesellschaft, der \u00d6sterreichischen Gesellschaft f\u00fcr Pneumologie, der \u00d6sterreichischen Gesellschaft f\u00fcr Allgemeinmedizin und Familienmedizin sowie der \u00d6sterreichischen Gesellschaft f\u00fcr Thoraxchirurgie erarbeiteten gemeinsame Empfehlungen zur Zielpopulation, Organisation, Qualit\u00e4tssicherung und Implementierung eines nationalen Screening-Programms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>Das Positionspapier definiert die Zielpopulation, Ein- und Ausschlusskriterien sowie Anforderungen an Diagnostik, Qualit\u00e4tssicherung, Organisation und interdisziplin\u00e4re Versorgung eines nationalen Screening-Programms. Die beteiligten Fachgesellschaften sprechen sich gemeinsam f\u00fcr die Einf\u00fchrung eines qualit\u00e4tsgesicherten, risikoadaptierten Lungenkarzinom-Screenings in \u00d6sterreich aus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Schlussfolgerung<\/jats:title>\n                    <jats:p>Die verf\u00fcgbare Evidenz spricht f\u00fcr die Einf\u00fchrung eines nationalen, qualit\u00e4tsgesicherten Lungenkarzinom-Screenings in \u00d6sterreich. Ein nationales Lungenkarzinom-Screening-Programm bietet die M\u00f6glichkeit, die Lungenkrebssterblichkeit nachhaltig zu senken, mehr Tumoren in kurativ behandelbaren Stadien zu diagnostizieren und die Versorgung von Hochrisikopersonen in \u00d6sterreich langfristig zu verbessern. Das vorliegende Positionspapier stellt eine wissenschaftlich fundierte Grundlage f\u00fcr die gesundheitspolitische Umsetzung eines nationalen Lungenkarzinom-Screenings dar.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00508-026-02813-w","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:15:00Z","timestamp":1789730100000},"page":"859-870","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implementierung eines nationalen Lungenkarzinom-Screening in \u00d6sterreich","Implementation of a national lung cancer screening in Austria"],"prefix":"10.1007","volume":"138","author":[{"given":"Romana","family":"Wass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerlig","family":"Widmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Bachler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klikovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"L\u00f6ffler-Ragg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Uggowitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kowatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arschang","family":"Valipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Wicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Tomaselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Kathrin","family":"Breyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Watzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Hochmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline","family":"Kink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Rowhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Lamprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Prosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"2813_CR1","volume-title":"Cancer incidence and mortality in Austria 2024","author":"Statistik Austria","year":"2026","unstructured":"Statistik Austria. Cancer incidence and mortality in Austria 2024. Vienna: Statistik Austria; 2026."},{"issue":"5","key":"2813_CR2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa1102873","volume":"365","author":"DR Aberle","year":"2011","unstructured":"Aberle\u00a0DR, Adams\u00a0AM, Berg\u00a0CD, et\u00a0al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395\u2013409.","journal-title":"N Engl J Med"},{"issue":"6","key":"2813_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1911793","volume":"382","author":"HJ de Koning","year":"2020","unstructured":"de Koning\u00a0HJ, van der Aalst\u00a0CM, de Jong\u00a0PA, et\u00a0al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503\u201313.","journal-title":"N Engl J Med"},{"issue":"4","key":"2813_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.annonc.2022.01.008","volume":"33","author":"U Pastorino","year":"2022","unstructured":"Pastorino\u00a0U, Boeri\u00a0M, Sestini\u00a0S, et\u00a0al. Baseline CT screening and microRNA risk stratification in the BioMILD trial. Ann Oncol. 2022;33(4):395\u2013405.","journal-title":"Ann Oncol"},{"issue":"9","key":"2813_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1136\/thoraxjnl-2016-209825","volume":"72","author":"E Paci","year":"2017","unstructured":"Paci\u00a0E, Puliti\u00a0D, Lopes Pegna\u00a0A, et\u00a0al. Mortality, survival and incidence in the ITALUNG randomized trial. Thorax. 2017;72(9):825\u201331.","journal-title":"Thorax"},{"issue":"10","key":"2813_CR6","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1164\/rccm.201408-1475OC","volume":"191","author":"M Infante","year":"2015","unstructured":"Infante\u00a0M, Cavuto\u00a0S, Lutman\u00a0FR, et\u00a0al. Long-term follow-up results of the DANTE trial. Am J Respir Crit Care Med. 2015;191(10):1166\u201375.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2813_CR7","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/JTO.0b013e3181a0d98f","volume":"4","author":"JH Pedersen","year":"2009","unstructured":"Pedersen\u00a0JH, Ashraf\u00a0H, Dirksen\u00a0A, et\u00a0al. The Danish randomized lung cancer CT screening trial. J\u00a0Thorac Oncol. 2009;4(5):608\u201314.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2813_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.lungcan.2007.05.009","volume":"58","author":"T Blanchon","year":"2007","unstructured":"Blanchon\u00a0T, Br\u00e9chot\u00a0JM, Grenier\u00a0PA, et\u00a0al. Baseline results of the Depiscan study. Lung Cancer. 2007;58(1):50\u20138.","journal-title":"Lung Cancer"},{"issue":"40","key":"2813_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20400","volume":"20","author":"JK Field","year":"2016","unstructured":"Field\u00a0JK, Duffy\u00a0SW, Baldwin\u00a0DR, et\u00a0al. The UK Lung Cancer Screening Trial (UKLS): a pilot randomized controlled trial. Health Technol Assess. 2016;20(40):1\u2013146.","journal-title":"Health Technol Assess"},{"issue":"6","key":"2813_CR10","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/ijc.32486","volume":"146","author":"N Becker","year":"2020","unstructured":"Becker\u00a0N, Motsch\u00a0E, Trotter\u00a0A, et\u00a0al. Lung cancer mortality reduction by LDCT screening: results from the randomized German LUSI trial. Int J Cancer. 2020;146(6):1503\u201313.","journal-title":"Int J Cancer"},{"issue":"2","key":"2813_CR11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00506-2019","volume":"55","author":"HU Kauczor","year":"2020","unstructured":"Kauczor\u00a0HU, Baird\u00a0AM, Blum\u00a0TG, et\u00a0al. ESR\/ERS statement paper on lung cancer screening. Eur Respir J. 2020;55(2)1900506.","journal-title":"Eur Respir J"},{"issue":"10","key":"2813_CR12","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2021.1117","volume":"325","author":"US Preventive Services Task Force","year":"2021","unstructured":"US Preventive Services Task Force. Lung Cancer Screening Recommendation Statement. JAMA. 2021;325(10):962\u201370.","journal-title":"JAMA"},{"issue":"suppl_4","key":"2813_CR13","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","volume":"28","author":"PE Postmus","year":"2017","unstructured":"Postmus\u00a0PE, Kerr\u00a0KM, Oudkerk\u00a0M, et\u00a0al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1\u2013iv21.","journal-title":"Ann Oncol"},{"key":"2813_CR14","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1007\/s00330-020-06727-7","volume":"30","author":"HU Kauczor","year":"2020","unstructured":"Kauczor HU, et al. ESR\/ERS statement paper on lung cancer screening\u00a0Eur Radiol. 2020;30(6):3277\u20133294.","journal-title":"Eur Radiol"},{"issue":"6","key":"2813_CR15","volume":"61","author":"HU Kauczor","year":"2023","unstructured":"Kauczor\u00a0HU, Heussel\u00a0CP, et\u00a0al. Developing a pan-European technical standard for a comprehensive high-quality lung cancer computed tomography screening programme: an ERS technical standard. Eur Respir J. 2023;61(6)2300128.","journal-title":"Eur Respir J"},{"key":"2813_CR16","unstructured":"European Council. Council Recommendation on Cancer Screening (EU). 2022, 2022\/0290 (NLE)."},{"key":"2813_CR17","unstructured":"European Respiratory Society. ERS welcomes approved EU Council Recommendation on cancer screening. ERS Press Release. 2022."},{"key":"2813_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-024-01814-5","volume":"15","author":"HU Kauczor","year":"2024","unstructured":"Kauczor\u00a0HU, et\u00a0al. SOLACE: Strengthening lung cancer screening in Europe. Insights Imaging. 2024;15:252.","journal-title":"Insights Imaging"},{"key":"2813_CR19","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1056\/NEJMoa1211776","volume":"368","author":"MC Tammem\u00e4gi","year":"2013","unstructured":"Tammem\u00e4gi\u00a0MC, Katki\u00a0HA, Hocking\u00a0WG, et\u00a0al. Selection criteria for lung-cancer screening using PLCOm2012. N Engl J Med. 2013;368:728\u201336.","journal-title":"N Engl J Med"},{"issue":"1","key":"2813_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S1470-2045(21)00590-8","volume":"23","author":"MC Tammem\u00e4gi","year":"2022","unstructured":"Tammem\u00e4gi\u00a0MC.\u00a0USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study Lancet Oncol. 2022;23(1):138\u201348.","journal-title":"Lancet Oncol"},{"issue":"10\u00a0Suppl","key":"2813_CR21","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1016\/j.jtho.2024.09.233","volume":"19","author":"J Vogel-Claussen","year":"2024","unstructured":"Vogel-Claussen\u00a0J, Bollmann\u00a0B, May\u00a0K, et\u00a0al. Effectiveness of NELSON vs PLCOm2012 lung screening criteria: final HANSE analysis. J\u00a0Thorac Oncol. 2024;19(10\u00a0Suppl):S129\u2013S30.","journal-title":"J Thorac Oncol"},{"key":"2813_CR22","unstructured":"NHS England. Targeted Lung Health Check Programme: Standard Protocol. 2022."},{"key":"2813_CR23","doi-asserted-by":"crossref","unstructured":"European Commission. 4\u2011IN THE LUNG RUN Project. 2020.","DOI":"10.1016\/j.fopow.2020.02.019"},{"issue":"8","key":"2813_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2188\/jea.JE20180039","volume":"29","author":"R Breyer-Kohansal","year":"2019","unstructured":"Breyer-Kohansal\u00a0R, Hartl\u00a0S, Burghuber\u00a0OC, et\u00a0al. The LEAD (Lung, Heart, Social, Body) Study: objectives, methodology, and external validity of the population-based cohort study. J\u00a0Epidemiol. 2019;29(8):315\u201324.","journal-title":"J Epidemiol"},{"key":"2813_CR25","unstructured":"European Society of Thoracic Imaging (ESTI). Technical standards for LDCT lung cancer screening. 2019."},{"issue":"12","key":"2813_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067263","volume":"12","author":"MP Revel","year":"2022","unstructured":"Revel\u00a0MP, Abdoul\u00a0H, Chassagnon\u00a0G,Canniff E, et\u00a0al. CAncer SCreening in French women using low-dose CT and Artificial intelligence for DEtection: the CASCADE study protocol. BMJ Open. 2022;12(12)e067263.","journal-title":"BMJ Open"},{"issue":"2","key":"2813_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2025.107736","volume":"69","author":"EE Kim","year":"2025","unstructured":"Kim\u00a0EE, Cenzer\u00a0I, Graham\u00a0FJ, et\u00a0al. Time to benefit for lung cancer screening: a systematic review and survival meta-analysis. Am J Prev Med. 2025;69(2)107736.","journal-title":"Am J Prev Med"},{"issue":"4","key":"2813_CR28","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.chest.2025.06.012","volume":"168","author":"Y Xie","year":"2025","unstructured":"Xie\u00a0Y, Zhang\u00a0Y, Zhang\u00a0P, et\u00a0al. Timing of screening benefit for lung cancer with low-dose CT imaging. Chest. 2025;168(4):1049\u201356.","journal-title":"Chest"},{"key":"2813_CR29","unstructured":"ESTI. Structured reporting template for lung cancer screening. 2019."},{"key":"2813_CR30","unstructured":"American Cancer Society. Lung Cancer Screening Guideline. CA Cancer J Clin. 2023."},{"key":"2813_CR31","unstructured":"IQWiG. Rapid report: Lungenkrebsscreening mit LDCT. 2020."},{"issue":"23","key":"2813_CR32","first-page":"387","volume":"120","author":"M Reck","year":"2023","unstructured":"Reck\u00a0M, Dettmer\u00a0S, Kauczor\u00a0HU, et\u00a0al. Lung cancer screening with LDCT\u2014review. Dtsch Arztebl Int. 2023;120(23):387\u201392.","journal-title":"Dtsch Arztebl Int"},{"key":"2813_CR33","unstructured":"Austrian Institute for Health Technology Assessment (AIHTA). Benefit\u2013risk assessment of LDCT screening in Austria. 2024."},{"issue":"1","key":"2813_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/sj.bjc.6605459","volume":"102","author":"KA van den Bergh","year":"2010","unstructured":"van den Bergh KA, et al. Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON). Br J Cancer. 2010 Jan 5;102(1):27-34","journal-title":"Br J Cancer"},{"issue":"2","key":"2813_CR35","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.231988","volume":"309","author":"CI Henschke","year":"2023","unstructured":"Henschke\u00a0CI, Yip\u00a0R, Shaham\u00a0D, et\u00a0al. A 20-year Follow-up of the International Early Lung Cancer Action Program (I-ELCAP). Radiology. 2023;309(2)e231988","journal-title":"Radiology"},{"issue":"1","key":"2813_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/1759-7714.13616","volume":"12","author":"A Buja","year":"2021","unstructured":"Buja\u00a0A, Rivera\u00a0M, De Polo\u00a0A, et\u00a0al. Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model. Thorac Cancer. 2021;12(1):13\u201320.","journal-title":"Thorac Cancer"},{"key":"2813_CR37","doi-asserted-by":"publisher","unstructured":"ten Berge H, et\u00a0al. Cost-effectiveness analysis of lung cancer screening in Austria. 2024, HTA Austria Report. https:\/\/doi.org\/10.3390\/cancers16152623","DOI":"10.3390\/cancers16152623"},{"key":"2813_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103446","volume":"88","author":"K de Nijs","year":"2025","unstructured":"de Nijs\u00a0K, Ten Haaf\u00a0K, Moldovanu\u00a0D, et\u00a0al. Influence of changing patterns in lung cancer treatment and survival on the cost-effectiveness of CT screening: a modeling study. EClinicalMedicine. 2025;88:103446.","journal-title":"EClinicalMedicine"},{"key":"2813_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108669","volume":"206","author":"D Zhong","year":"2025","unstructured":"Zhong\u00a0D, Sidorenkov\u00a0G, Poelhekken\u00a0K, et\u00a0al. Cost-effectiveness and budget impact of lung cancer screening in time of immunotherapy. Lung Cancer. 2025;206:108115.","journal-title":"Lung Cancer"},{"issue":"1","key":"2813_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41533-026-00482-w","volume":"36","author":"Z Fan","year":"2026","unstructured":"Fan\u00a0Z, Zheng\u00a0M, Guan\u00a0Z, et\u00a0al. Cost-effectiveness of lung cancer screening: insights from risk stratification, guidelines, and emerging technologies\u2014a systematic review. NPJ Prim Care Respir Med. 2026;36(1)15.","journal-title":"NPJ Prim Care Respir Med"},{"key":"2813_CR41","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.lungcan.2018.07.036","volume":"124","author":"F Hofer","year":"2018","unstructured":"Hofer\u00a0F, et\u00a0al. Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach. Lung Cancer. 2018;124:189-198.","journal-title":"Lung Cancer"},{"key":"2813_CR42","doi-asserted-by":"publisher","unstructured":"Behr S, et\u00a0al. Economic evaluation of LDCT in the UK. Br J Cancer. 2023. https:\/\/doi.org\/10.1007\/s40273-022-01238-3","DOI":"10.1007\/s40273-022-01238-3"},{"issue":"2","key":"2813_CR43","volume":"7","author":"I Toumazis","year":"2021","unstructured":"Toumazis\u00a0I, et\u00a0al. Cost-effectiveness of lung cancer screening in the US. JAMA Oncol. 2021;7(2)e205347.","journal-title":"JAMA Oncol"},{"issue":"11","key":"2813_CR44","volume":"14","author":"K Ten Haaf","year":"2017","unstructured":"Ten Haaf\u00a0K, et\u00a0al.\u00a0Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada PLoS Med. 2017;14(2)e1002225","journal-title":"PLoS Med"},{"issue":"6","key":"2813_CR45","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamaoncol.2015.2472","volume":"1","author":"PM McMahon","year":"2015","unstructured":"Goffin JR, et al. Cost-effectiveness of Lung Cancer Screening in Canada.\u00a0JAMA Oncol . 2015 Sep;1(6):807-13","journal-title":"JAMA Oncol"},{"key":"2813_CR46","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.7288","volume":"185","author":"PM Cinciripini","year":"2025","unstructured":"Cinciripini PM, et al. Smoking Cessation Interventions in the Lung Cancer Screening Setting A Randomized Clinical Trial,\u00a02025 Mar 1;185(3):284-291.","journal-title":"JAMA Intern Med"},{"key":"2813_CR47","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1136\/thoraxjnl-2016-209690","volume":"72","author":"K Brain","year":"2017","unstructured":"Brain\u00a0K, Carter\u00a0B, Lifford\u00a0KJ, et\u00a0al.\u00a0Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial Thorax. 2017;72:912\u20138.","journal-title":"Thorax"},{"issue":"4","key":"2813_CR48","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00533-2023","volume":"62","author":"EL O\u2019Dowd","year":"2023","unstructured":"O\u2019Dowd\u00a0EL, Tietzova\u00a0I, Bartlett\u00a0E, et\u00a0al. ERS\/ESTS\/ESTRO\/ESR\/ESTI\/EFOMP statement on management of incidental findings from low-dose CT screening for lung cancer. Eur Respir J. 2023;62(4)2300533.","journal-title":"Eur Respir J"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-026-02813-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-026-02813-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-026-02813-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:51:25Z","timestamp":1791463885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-026-02813-w"}},"subtitle":["Positionspapier der \u00d6sterreichischen R\u00f6ntgengesellschaft (\u00d6RG), der \u00d6sterreichischen Gesellschaft f\u00fcr Pneumologie (\u00d6GP), der \u00d6sterreichischen Gesellschaft f\u00fcr Allgemeinmedizin und Familienmedizin (\u00d6GAM) und der \u00d6sterreichischen Gesellschaft f\u00fcr Thoraxchirurgie (\u00d6GTC)","Position paper of the Austrian Radiological Society (\u00d6RG), the Austrian Society of Pneumology (\u00d6GP), the Austrian Society of General Practice and Family Medicine (\u00d6GAM) and the Austrian Society of Thoracic Surgery (\u00d6GTC)"],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":48,"journal-issue":{"issue":"S14","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2813"],"URL":"https:\/\/doi.org\/10.1007\/s00508-026-02813-w","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"assertion":[{"value":"4 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.\u00a0Wass: Sprecherhonorare: Amgen, AstraZeneca, BMS, Johnson & Johnson, MSD, Roche; Advisory Boards: AstraZeneca, BeOne, BMS, Boehringer Ingelheim, Gilead, Johnson & Johnson, MSD, PharmaMar, Roche. A.\u00a0Valipour: Vortragshonorare und\/oder wissenschaftliche bzw. educational Grants von AbbVie, Accord, Amgen, AstraZeneca, BeOne, BMS, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, MSD, Pharma Mar, Pfizer, Pierre Fabre, Roche, Sanofi, Takeda. M.\u00a0Hochmair: Sprecherhonorare und Advisory Boards: Amgen, AstraZeneca, BMS, Eli Lilly, Johnson & Johnson, MSD, Pfizer, Roche, Takeda. H.\u00a0Prosch: Sprecherhonorare: AstraZeneca, BMS, Boehringer Ingelheim, Bracco, Daiichi Sankyo, Johnson & Johnson, MSD, Novartis, Roche, Sanofi, Siemens Healthineers, Takeda; Advisory Boards: BMS, Boehringer Ingelheim, Janssen, MSD, Roche, Sanofi. Forschungsunterst\u00fctzung: Boehringer Ingelheim, AstraZeneca, Siemens Healthineers and the Christian Doppler Research Association, EU Commission (EU4Health, Horizon Europe Health). G.\u00a0Widmann, H.\u00a0Bachler, T.\u00a0Klikovits, J.\u00a0L\u00f6ffler-Ragg, M.\u00a0Uggowitzer, P.\u00a0Kowatsch, F.\u00a0Augustin, K.\u00a0Wicke, F.\u00a0Tomaselli, M.-K.\u00a0Breyer, S.\u00a0Watzka, E.\u00a0Kink, M.\u00a0Rowhani, B.\u00a0Lamprecht und geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}